In July 1997, Novartis submitted a new patent software in Switzerland on the beta crystalline method of imatinib mesylate (the mesylate salt of imatinib). The "beta crystalline kind" from the molecule is a certain https://craigrvcp724872.blog5.net/72432752/examine-this-report-on-カソデックス-ビカルタミド